title: Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study.
abstract: The aim of this 6-month observational study was to examine which clinical, eating- and lifestyle-related factors were associated with weight gain in patients initiating or switching to oral olanzapine for the treatment of schizophrenia or bipolar mania. A total of 622 outpatients in four countries (China, Mexico, Romania, Taiwan) were assessed at monthly intervals for up to 6 months. Mixed model repeated-measures analysis, adjusted for baseline weight, was used to identify which factors were associated with weight gain during olanzapine therapy. After 6 months of therapy, the LS mean weight change was +4.1 kg and 43.9% of the patients had significant (> or = 7%) weight gain. Early significant weight gain after 2 months of therapy occurred in 23.4% of the patients and these patients gained significantly more weight overall. Ten factors were associated with weight gain during 6 months of olanzapine therapy in an exploratory multivariate analysis: country, housing conditions, stronger appetite, excessive amount of food needed to feel full, eating until uncomfortably full, thoughts preoccupied with food, meal location, increased meal frequency, evening snack consumption, and a lower amount of vigorous exercise. These results indicate that the influence of environmental, eating- and lifestyle-related factors should be considered when assessing weight gain during olanzapine therapy.
authors.affiliation: Neuroscience Research, Lilly Hungaria Kft, Budapest, Hungary. treuert@lilly.com
authors.forename: Tamás
authors.initials: T
authors.lastname: Treuer
authors.forename: Vicki Poole
authors.initials: VP
authors.lastname: Hoffmann
authors.forename: Antony Kuang-Peng
authors.initials: AK
authors.lastname: Chen
authors.forename: Victoria
authors.initials: V
authors.lastname: Irimia
authors.forename: Magdalena
authors.initials: M
authors.lastname: Ocampo
authors.forename: Gang
authors.initials: G
authors.lastname: Wang
authors.forename: Pritibha
authors.initials: P
authors.lastname: Singh
authors.forename: Susanna
authors.initials: S
authors.lastname: Holt
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000453:epidemiology*; D003710:Demography; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005247:Feeding Behavior; D005260:Female; D006304:Health Status; D006801:Humans; D007391:International Cooperation; D008019:Life Style; D008297:Male; D009765:Obesity / Q000139:chemically induced* / Q000453:epidemiology*; D000077152:Olanzapine; D011446:Prospective Studies; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D012720:Severity of Illness Index; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine